Premium
Factor (G‐CSFa) Enhances Peripheral Platelet Recovery in C57 Radiotherapy Mice and No Immunogenicity in Rats
Author(s) -
Jie Zhenwang,
Shi Keyong,
Chu Chang,
Ding Xinxin,
Jiang Yongping
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.785.2
Subject(s) - immunogenicity , mutagenesis , in vivo , platelet , amino acid , antibody , in vitro , recombinant dna , chemistry , peripheral , biochemistry , pharmacology , biology , immunology , mutation , gene , medicine , genetics
Using site‐direct mutagenesis and recombinant DNA technology, we had previously obtained a structurally modified derivative of human G‐CSF termed G‐CSFa, which has three extra amino acid residues added at the amino‐terminus. The novel rhG‐CSFa displayed a lower plasma clearance rate, suggesting a much extended plasma functional half‐life. Previous studies showed that G‐CSFa is more potent than the wild‐type counterpart in stimulating proliferation and differentiation of myeloid cells of the granulocytic lineage, both in vitro and in vivo . Here, we show that G‐CSFa can significantly accelerate peripheral platelet recovery in C57BL/6 mice exposed to irradiation. In the G‐CSFa treatment group, the peripheral platelet count has fully recovered on day 19( list the specific number),whereas in vehicle control group, it was on a dramatically low level.(list number) We further demonstrate that G‐CSFa is not immunogenic in rats, by confirming the absence of any binding antibodies, or neutralizing antibodies, to G‐CSFa in the sera of Sprague‐Dawley rats following repeated G‐CSFa administration. Taken together, these findings further support the benefits of G‐CSFa for clinical therapy.